首页> 美国卫生研究院文献>Scientific Reports >Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study
【2h】

Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study

机译:通过分子动力学研究探索批准的选择性去甲肾上腺素再摄取抑制剂和瑞波西汀对映体的抑制机理

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Selective norepinephrine reuptake inhibitors (sNRIs) provide an effective class of approved antipsychotics, whose inhibitory mechanism could facilitate the discovery of privileged scaffolds with enhanced drug efficacy. However, the crystal structure of human norepinephrine transporter (hNET) has not been determined yet and the inhibitory mechanism of sNRIs remains elusive. In this work, multiple computational methods were integrated to explore the inhibitory mechanism of approved sNRIs (atomoxetine, maprotiline, reboxetine and viloxazine), and 3 lines of evidences were provided to verify the calculation results. Consequently, a binding mode defined by interactions between three chemical moieties in sNRIs and eleven residues in hNET was identified as shared by approved sNRIs. In the meantime, binding modes of reboxetine’s enantiomers with hNET were compared. 6 key residues favoring the binding of (S, S)-reboxetine over that of (R, R)-reboxetine were discovered. This is the first study reporting that those 11 residues are the common determinants for the binding of approved sNRIs. The identified binding mode shed light on the inhibitory mechanism of approved sNRIs, which could help identify novel scaffolds with improved drug efficacy.
机译:选择性去甲肾上腺素再摄取抑制剂(sNRI)提供了一类有效的已批准的抗精神病药,其抑制机制可以促进发现具有增强药物功效的特异支架。然而,人类去甲肾上腺素转运蛋白(hNET)的晶体结构尚未确定,sNRIs的抑制机制仍然难以捉摸。在这项工作中,综合了多种计算方法以探讨批准的sNRIs(阿托西汀,马普替林,瑞波西汀和维洛嗪)的抑制机理,并提供了3条证据来验证计算结果。因此,由sNRI中的三个化学部分与hNET中的十一个残基之间的相互作用所定义的结合模式被鉴定为已批准的sNRI所共有。同时,比较了瑞波西汀对映体与hNET的结合方式。发现了6个比(R,R)-瑞波西汀有利于(S,S)-瑞波西汀结合的关键残基。这是第一项报道该11个残基是批准的sNRI结合的共同决定因素的研究。鉴定的结合模式阐明了已批准的sNRI的抑制机制,这可能有助于鉴定具有改善的药物功效的新型支架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号